$ARTL
ARTELO BIOSCIENCES, INC. Stock $artl

$artl Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-K Financial Statement

#000164033420002722 Filed on November 04, 2020

Income Statement

Concept	2020 Q4	2020	2019 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$840.0K	$2.770M	$720.0K
YoY Change	25.37%	30.66%	100.0%
% of Gross Profit
Research & Development	$595.0K	$1.919M	$230.0K
YoY Change	-11.19%	75.73%	-30.3%
% of Gross Profit
Depreciation & Amortization	$0.00	$500.00	$0.00
YoY Change		-1.96%
% of Gross Profit
Operating Expenses	$1.436M	$4.686M	$950.0K
YoY Change	7.16%	46.0%	37.68%
Operating Profit	-$1.436M	-$4.686M
YoY Change		46.0%
Interest Expense	$0.00	$30.00K	$110.0K
YoY Change	-100.0%	-97.03%
% of Operating Profit
Other Income/Expense, Net	$1.000K	$31.00K	$0.00
YoY Change		-97.01%
Pretax Income	-$1.430M	-$4.650M	-$850.0K
YoY Change	9.16%	114.29%	23.19%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$1.435M	-$4.655M	-$850.0K
YoY Change	9.85%	114.3%	23.19%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$139.9K	-$1.253M	-$283.3K
COMMON SHARES
Basic Shares Outstanding	15.11M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q4	2020	2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.390M	$2.140M	$4.420M
YoY Change	119.29%	-51.58%	1200.0%
Cash & Equivalents	$5.783M	$2.140M	$4.424M
Short-Term Investments		$3.436M
Other Short-Term Assets	$110.0K	$200.0K	$10.00K
YoY Change	22.22%	1900.0%	-75.0%
Inventory
Prepaid Expenses	$111.1K		$18.62K
Receivables
Other Receivables
Total Short-Term Assets	$7.500M	$2.340M	$4.443M
YoY Change	113.68%	-47.3%	1010.65%
LONG-TERM ASSETS
Property, Plant & Equipment	$185.00	$0.00	$721.00
YoY Change	-69.06%
Goodwill
YoY Change
Intangibles			$2.039M
YoY Change
Long-Term Investments
YoY Change
Other Assets		$189.0K
YoY Change
Total Long-Term Assets	$2.040M	$2.040M	$2.040M
YoY Change	0.0%	0.0%
TOTAL ASSETS
Total Short-Term Assets	$7.500M	$2.340M	$4.443M
Total Long-Term Assets	$2.040M	$2.040M	$2.040M
Total Assets	$9.540M	$4.380M	$6.483M
YoY Change	71.89%	-32.41%	1520.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$470.0K	$490.0K	$639.4K
YoY Change	-17.54%	40.0%	20.64%
Accrued Expenses		$28.00K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$490.0K	$500.0K	$1.022M
YoY Change	-15.52%	-50.98%	92.74%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities		$67.00K
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$490.0K	$500.0K	$1.022M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$490.0K	$500.0K	$1.020M
YoY Change	-15.52%	-50.98%	92.45%
SHAREHOLDERS EQUITY
Retained Earnings			-$4.811M
YoY Change
Common Stock	$15.11K		$3.354K
YoY Change	341.1%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.435M	$3.870M	$5.460M
YoY Change
Total Liabilities & Shareholders Equity	$9.540M	$4.380M	$6.483M
YoY Change	71.96%	-32.41%	1520.68%

Cashflow Statement

Concept	2020 Q4	2020	2019 Q3
OPERATING ACTIVITIES
Net Income	-$1.435M	-$4.655M	-$850.0K
YoY Change	9.85%	114.3%	23.19%
Depreciation, Depletion And Amortization	$0.00	$500.00	$0.00
YoY Change		-1.96%
Cash From Operating Activities	-$1.320M	-$4.347M	-$1.060M
YoY Change	25.71%	55.66%	107.84%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	-$1.500M
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities		-$3.439M
YoY Change
Cash From Investing Activities	$0.00	$0.00	-$1.500M
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$6.579M	$1.978M
YoY Change		-76.39%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$6.579M	$1.981M	6.700M
YoY Change	-65890.0%	-76.35%	1164.15%
NET CHANGE
Cash From Operating Activities	-$1.320M	-$4.347M	-1.060M
Cash From Investing Activities	$0.00	$0.00	-1.500M
Cash From Financing Activities	$6.579M	$1.981M	6.700M
Net Change In Cash	$5.259M	-$2.366M	4.140M
YoY Change	-601.2%	-157.93%	20600.0%
FREE CASH FLOW
Cash From Operating Activities	-$1.320M	-$4.347M	-$1.060M
Capital Expenditures		$0.00	-$1.500M
Free Cash Flow		-$4.347M	$440.0K
YoY Change		236.28%	-186.27%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001621221
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--08-31
CY2020	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Entity Small Business EntitySmallBusiness	true
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Registrant Name EntityRegistrantName	ARTELO BIOSCIENCES, INC.
CY2020Q3	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2019Q3	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-08-31
CY2020	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
CY2020	dei	Trading Symbol TradingSymbol	ARTL
CY2020Q1	dei	Entity Public Float EntityPublicFloat	2970416	USD
CY2020Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	15111587	shares
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2142072	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4423965	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	337424	USD
CY2020Q3	artl	Prepaid Expenses And Deposits Current PrepaidExpensesAndDepositsCurrent	195127	USD
CY2019Q3	artl	Prepaid Expenses And Deposits Current PrepaidExpensesAndDepositsCurrent	18623	USD
CY2020Q3	us-gaap	Assets Current AssetsCurrent	2337199	USD
CY2019Q3	us-gaap	Assets Current AssetsCurrent	4442588	USD
CY2020Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1363	USD
CY2019Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	792	USD
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	246	USD
CY2019Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	721	USD
CY2020Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2039417	USD
CY2019Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2039417	USD
CY2020Q3	us-gaap	Assets Assets	4376862	USD
CY2019Q3	us-gaap	Assets Assets	6482726	USD
CY2020Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	490218	USD
CY2019Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	348863	USD
CY2020Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	11959	USD
CY2019Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	3732	USD
CY2019Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	29501	USD
CY2020Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	USD
CY2019Q3	artl	Current Stock Payable CurrentStockPayable	639417	USD
CY2020Q3	us-gaap	Liabilities Current LiabilitiesCurrent	502177	USD
CY2019Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1021513	USD
CY2019Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	6250000	shares
CY2020Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	6250000	shares
CY2019Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2020Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	18750000	shares
CY2020Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	18750000	shares
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2020Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4991587	shares
CY2019Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3353616	shares
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4991587	shares
CY2019Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3353616	shares
CY2020Q3	us-gaap	Common Stock Value CommonStockValue	4992	USD
CY2019Q3	us-gaap	Common Stock Value CommonStockValue	3354	USD
CY2020Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	13271549	USD
CY2019Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	10278421	USD
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-9465618	USD
CY2019Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4810756	USD
CY2020Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	63762	USD
CY2019Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-9806	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	3874685	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	5461213	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	-134974	USD
CY2020Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4376862	USD
CY2019Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6482726	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1788684	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	952334	USD
CY2020	us-gaap	Professional Fees ProfessionalFees	977672	USD
CY2019	us-gaap	Professional Fees ProfessionalFees	1164695	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1918919	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1091992	USD
CY2020	us-gaap	Depreciation Nonproduction DepreciationNonproduction	500	USD
CY2019	us-gaap	Depreciation Nonproduction DepreciationNonproduction	510	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	4685775	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	3209531	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-4685775	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-3209531	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2169702	USD
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.26
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.00
CY2020	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	1412	USD
CY2019	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	31256	USD
CY2020	artl	Change In Fair Value For Period Of Warrant Derivative Liability ChangeInFairValueForPeriodOfWarrantDerivativeLiability	29501	USD
CY2019	artl	Change In Fair Value For Period Of Warrant Derivative Liability ChangeInFairValueForPeriodOfWarrantDerivativeLiability	1006099	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	30913	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1037355	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-4654862	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-2172176	USD
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	73568	USD
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	2474	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	73568	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	2474	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4581294	USD
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	3707650	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2172465	shares
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	8376379	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1977691	USD
CY2019	artl	Stock Issued During Period Value Issued For Services Three StockIssuedDuringPeriodValueIssuedForServicesThree	52000	USD
CY2020	artl	Stock Issued During Period Value Issued For Services Three StockIssuedDuringPeriodValueIssuedForServicesThree	44500	USD
CY2019	artl	Stock Issued During Period Value Issued For Services Related Party StockIssuedDuringPeriodValueIssuedForServicesRelatedParty	240000	USD
CY2019	artl	Reclass Of Warrant Derivative Liability From Equity ReclassOfWarrantDerivativeLiabilityFromEquity	1035600	USD
CY2019	artl	Stock Issued During Period Value Issued For Services Two StockIssuedDuringPeriodValueIssuedForServicesTwo	133110	USD
CY2020	artl	Stock Issued During Period Value Issued For Services Two StockIssuedDuringPeriodValueIssuedForServicesTwo	335766	USD
CY2020	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	539417	USD
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	100000	USD
CY2020	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	2500	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	335766	USD
CY2020	artl	Adjustments To Additional Paid In Capital Refund For Fractional Stock AdjustmentsToAdditionalPaidInCapitalRefundForFractionalStock	-108	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	377766	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	425110	USD
CY2020	us-gaap	Depreciation Depreciation	500	USD
CY2019	us-gaap	Depreciation Depreciation	510	USD
CY2019	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	100000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	169264	USD
CY2019	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-27048	USD
CY2019	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-13340	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	127979	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-180409	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4347382	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2792676	USD
CY2019	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	688	USD
CY2019	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1500000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1500688	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1977691	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8376379	USD
CY2020	artl	Refund For Fractional Stock RefundForFractionalStock	-108	USD
CY2020	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	7863	USD
CY2019	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	18276	USD
CY2020	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-4710	USD
CY2019	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-17228	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1980736	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8377427	USD
CY2020	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	84753	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	2478	USD
CY2020	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2281893	USD
CY2019	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	4086541	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
CY2019	artl	Common Shares Issued For Deposit Of Acquisition Of License CommonSharesIssuedForDepositOfAcquisitionOfLicense	539417	USD
CY2019	us-gaap	Stock Issued1 StockIssued1	13	USD
CY2020	artl	Common Shares Issued For Acquisition Of License Offset Against Stock Payable CommonSharesIssuedForAcquisitionOfLicenseOffsetAgainstStockPayable	539417	USD
CY2020	artl	Common Shares Issued For Settlement Of Stock Payable CommonSharesIssuedForSettlementOfStockPayable	100000	USD
CY2020	artl	Additional Issuance Series D Shares Per Terms Subscription Agreements AdditionalIssuanceSeriesDSharesPerTermsSubscriptionAgreements	7	USD
CY2020	artl	Cancellation Of Common Shares CancellationOfCommonShares	6	USD
CY2020	us-gaap	Nature Of Operations NatureOfOperations	<p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS</strong></span></span></span></span></span></span></p><p style="MARGIN:0px"> </p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>ARTELO BIOSCIENCES, INC. (“we”, “us”, “our”, the “Company”) is a Nevada corporation incorporated on May 2, 2011 and based in San Diego County, California. The accounting and reporting policies of the Company conform to accounting principles generally accepted in the United States of America, and the Company’s fiscal year end is August 31.</span></span></span></span></span></span></p><p style="MARGIN:0px"> </p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>The Company registered fully owned subsidiaries in Ireland, Trinity Reliant Ventures Limited, on November 11, 2016 and in the UK, Trinity Research & Development Limited, on June 2, 2017. On January 8, 2020 Trinity Research and Development Limited changed its name to Artelo Biosciences Limited. The Company incorporated a fully owned subsidiary in Canada, Artelo Biosciences Corporation, on March 18, 2020. Operations in the subsidiaries have been consolidated in the financial statements.</span></span></span></span></span></span></p><p style="MARGIN:0px;text-align:justify"> </p><div><div><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We are a clinical stage biopharmaceutical company focused on developing and commercializing treatments intended to modulate the endocannabinoid system.</span></span></p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"> </p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em>Liquidity</em></span></span></p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"> </p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has incurred losses for the past several years and a net loss of $4.7 million during the year ended August 31, 2020. Subsequent to August 31, 2020, we completed a public offering for net proceeds of approximately $6.6 million, which substantially increased our cash and cash equivalents and improved our working capital position (Note 9). Consequently, our existing cash resources and cash received from the public offering are expected to provide sufficient funds to carry out our planned operations for 12 months from the date that our consolidated financial statements are issued.</span></span></p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"> </p><p style="margin:0px;font-family:times new roman;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our continuation as a <span>going </span>concern<span style="background:white"> for a period beyond those 12 months will be dependent upon our ability to obtain adequate additional financing, as our operations are capital intensive, and future capital expenditures and additional working capital are expected. The Company's independent registered public accounting firm expressed in its report on the Company's financial statements for the year ended August 31, 2019 that there was substantial doubt about the Company's ability to continue as a going concern. Based on management's plans and the significant capital raised on October 14, 2020, that substantial doubt has been alleviated.</span></span></span></p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"> </p></div></div><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><i>Reverse stock split</i></span></span></span></span></span></span></p><p style="MARGIN:0px;text-align:justify"> </p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The Company filed a Certificate of Change with the Secretary of State of Nevada, pursuant to which, effective on June 20, 2019, the Company effected a one-for-eight reverse split of its authorized and issued and outstanding common stock (the “Reverse Stock Split”). The number of authorized shares of common stock was reduced from 150,000,000 to 18,750,000. The Company’s authorized Preferred Stock was reduced from 50,000,000 to 6,250,000. All share and per share information in these financial statements retroactively reflect this reverse stock split.</span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"> </p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><span><span>Covid 19</span></span></em></span></span></p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"> </p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>As the COVID-19 pandemic is still evolving at this time and much of its impact remains unknown, the Company is not able to predict the impact it may have on the development of its product candidates and business. The severity of the COVID-19 pandemic could also negatively impact the Company’s access to its existing supply chain by delaying the delivery of key raw materials used in its product candidates and therefore delay the delivery of such products for use in its clinical trials. Any of these results could have a material adverse impact to our business.</span></span></span></span></p>
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	6600000	USD
CY2020	us-gaap	Property Plant And Equipment Depreciation Methods PropertyPlantAndEquipmentDepreciationMethods	straight-line method
CY2020	artl	Weighted Average Exercise Price Granted WeightedAverageExercisePriceGranted	0	USD
CY2020	artl	Number Of Warrant Granted NumberOfWarrantGranted	0	shares
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<div><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><i>Use of Estimates</i></strong></span></span></p><p style="MARGIN:0px"> </p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.</span></span></p></div>
CY2020	artl	Weighted Average Number Of Diluted Instruments WeightedAverageNumberOfDilutedInstruments	2616771	shares
CY2019	artl	Weighted Average Number Of Diluted Instruments WeightedAverageNumberOfDilutedInstruments	2568937	shares
CY2019	artl	Weighted Average Exercise Price Granted WeightedAverageExercisePriceGranted	7.51	USD
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><i>Concentrations of Credit Risk</i></strong></span></span></p><p style="MARGIN:0px"> </p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company’s financial instruments that are exposed to concentrations of credit risk primarily consist of its cash and cash equivalents. The Company places its cash and cash equivalents with financial institutions of high credit worthiness. At times, its cash and cash equivalents with a particular financial institution may exceed any applicable government insurance limits. The Company’s management plans to assess the financial strength and credit worthiness of any parties to which it extends funds, and as such, it believes that any associated credit risk exposures are limited.</span></span></p></div>
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	52000	USD
CY2020	artl	Unamortized Stock Base Compensation UnamortizedStockBaseCompensation	33833	USD
CY2020	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><em><strong>Reclassification of Prior Year Amounts</strong></em></p><p style="margin:0pt"> </p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">Certain prior year amounts in the Consolidated Statements of Operations and Comprehensive Loss have been reclassified to conform with current year presentation.</p></div>
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	42000	USD
CY2019Q2	artl	Number Of Warrant Purchase NumberOfWarrantPurchase	1	Warrant
CY2019Q2	artl	Number Of Purchase Common Stock Shares NumberOfPurchaseCommonStockShares	1	Warrant
CY2019Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	6.4575
CY2019Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	1300813	shares
CY2018Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	495306	shares
CY2019Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2334937	shares
CY2020Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2334937	shares
CY2018Q3	artl	Weighted Average Exercise Price WeightedAverageExercisePrice	10.40	USD
CY2019Q3	artl	Weighted Average Exercise Price WeightedAverageExercisePrice	8.12	USD
CY2020Q3	artl	Weighted Average Exercise Price WeightedAverageExercisePrice	8.12	USD
CY2018	artl	Warrants Weighted Average Life WarrantsWeightedAverageLife	P4Y2M23D
CY2019	artl	Warrants Weighted Average Life WarrantsWeightedAverageLife	P4Y3M18D
CY2020	artl	Warrants Weighted Average Life WarrantsWeightedAverageLife	P3Y3M18D
CY2019	artl	Number Of Warrant Granted NumberOfWarrantGranted	1839631	shares
CY2019	artl	Warrant Weighted Average Life Granted WarrantWeightedAverageLifeGranted	P4Y10M6D
CY2019	artl	Number Of Warrant Forfeited NumberOfWarrantForfeited	0	shares
CY2020	artl	Number Of Warrant Forfeited NumberOfWarrantForfeited	0	shares
CY2019	artl	Weighted Average Exercise Price Forfeited WeightedAverageExercisePriceForfeited	0	USD
CY2020	artl	Weighted Average Exercise Price Forfeited WeightedAverageExercisePriceForfeited	0	USD
CY2019	artl	Weighted Average Exercise Price Exercised WeightedAverageExercisePriceExercised	0	USD
CY2020	artl	Weighted Average Exercise Price Exercised WeightedAverageExercisePriceExercised	0	USD
CY2019	artl	Number Of Warrant Exercised NumberOfWarrantExercised	0	shares
CY2020	artl	Number Of Warrant Exercised NumberOfWarrantExercised	0	shares
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	184000	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	74000	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.55	pure
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.58	pure
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0167	pure
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0140	pure
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	50000	shares
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	234000	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	281834	shares
CY2018Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	10.80
CY2019Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	3.88
CY2020Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	3.57
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y11M19D
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y9M10D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y10M24D
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.01
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.48
CY2019	artl	Share Based Payment Stock Option Granted Weighted Average Remaining Life ShareBasedPaymentStockOptionGrantedWeightedAverageRemainingLife	P10Y
CY2020	artl	Share Based Payment Stock Option Granted Weighted Average Remaining Life ShareBasedPaymentStockOptionGrantedWeightedAverageRemainingLife	P10Y
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	0	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	26166	shares
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	3.31
CY2020	artl	Share Based Payment Stock Option Forfeited Canceled Weighted Average Remaining Life ShareBasedPaymentStockOptionForfeitedCanceledWeightedAverageRemainingLife	P9Y6M29D
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.57
CY2020Q3	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	151505	shares
CY2020Q3	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	3.92
CY2020Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	8559733	USD
CY2020Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1797544	USD
CY2019Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1058724	USD
CY2020Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1797544	USD
CY2019Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1058724	USD
CY2020Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2019Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD

Files In Submission

Name	View Source	Status
0001640334-20-002722-index-headers.html	Edgar Link	pending
0001640334-20-002722-index.html	Edgar Link	pending
0001640334-20-002722.txt	Edgar Link	pending
0001640334-20-002722-xbrl.zip	Edgar Link	pending
artl-20200831.xml	Edgar Link	completed
artl-20200831.xsd	Edgar Link	pending
artl-20200831_cal.xml	Edgar Link	unprocessable
artl-20200831_def.xml	Edgar Link	unprocessable
artl-20200831_lab.xml	Edgar Link	unprocessable
artl-20200831_pre.xml	Edgar Link	unprocessable
artl_10k.htm	Edgar Link	pending
artl_ex311.htm	Edgar Link	pending
artl_ex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ARTL
ARTELO BIOSCIENCES, INC. Stock $artl

2020 Q4 Form 10-K Financial Statement

#000164033420002722 Filed on November 04, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARTL ARTELO BIOSCIENCES, INC. Stock $artl

2020 Q4 Form 10-K Financial Statement

#000164033420002722 Filed on November 04, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARTL
ARTELO BIOSCIENCES, INC. Stock $artl